1. Home
  2. GRDN vs VCEL Comparison

GRDN vs VCEL Comparison

Compare GRDN & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardian Pharmacy Services Inc.

GRDN

Guardian Pharmacy Services Inc.

N/A

Current Price

$33.37

Market Cap

2.1B

ML Signal

N/A

Logo Vericel Corporation

VCEL

Vericel Corporation

N/A

Current Price

$31.85

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GRDN
VCEL
Founded
2004
1989
Country
United States
United States
Employees
3400
398
Industry
Retail-Drug Stores and Proprietary Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
GRDN
VCEL
Price
$33.37
$31.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$33.33
$58.50
AVG Volume (30 Days)
177.2K
416.0K
Earning Date
01-01-0001
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.00
EPS
N/A
0.32
Revenue
N/A
$276,259,000.00
Revenue This Year
$1.13
$19.09
Revenue Next Year
$9.97
$17.96
P/E Ratio
$117.77
$102.78
Revenue Growth
N/A
16.45
52 Week Low
$19.17
$29.24
52 Week High
$37.43
$48.75

Technical Indicators

Market Signals
Indicator
GRDN
VCEL
Relative Strength Index (RSI) 53.23 32.11
Support Level $28.07 $31.34
Resistance Level $34.98 $38.48
Average True Range (ATR) 1.63 1.39
MACD -0.12 -0.40
Stochastic Oscillator 46.46 4.88

Price Performance

Historical Comparison
GRDN
VCEL

About GRDN Guardian Pharmacy Services Inc.

Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.

About VCEL Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Share on Social Networks: